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Abstract: Computational design of small molecule putative inhibitors of Polo-like kinase 1 (Plk1) is presented. Plk1, which regulates 
the cell cycle, is often over expressed in cancers. Down regulation of Plk1 has been shown to inhibit tumor progression. Most kinase 
inhibitors interact with the ATP binding site on Plk1, which is highly conserved. This makes the development of Plk1-specific inhibitors 
challenging, since different kinases have similar ATP sites. However, Plk1 also contains a unique region called the polo-box domain 
(PBD), which is absent from other kinases. In this study, the PBD site was used as a target for designed Plk1 putative inhibitors. Com-
mon structural features of several experimentally known Plk1 ligands were first identified. The findings were used to design small 
molecules that specifically bonded Plk1. Drug likeness and possible toxicities of the molecules were investigated. Molecules with no 
implied toxicities and optimal drug likeness values were used for docking studies. Several molecules were identified that made stable 
complexes only with Plk1 and LYN kinases, but not with other kinases. One molecule was found to bind exclusively the PBD site of 
Plk1. Possible utilization of the designed molecules in drugs against cancers with over expressed Plk1 is discussed.
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Introduction
Protein kinases alter the activity of certain proteins 
by  phosphorylation,  a  process  in  which  a  phos-
phate group is transferred from a donor molecule 
(for example, ATP1) to an amino acid with a free 
hydroxyl group. The study of kinases is important 
due to their involvement in many diseases, includ-
ing cancer.2 The cell cycle in cancer cells is often 
characterized by faulty signaling pathways.3,4 Inhib-
iting cell cycle regulators offers promise for cancer 
treatment.5
Protein  kinases  control  many  complex  cellular 
processes, such as signal transduction, and are thus 
highly regulated.6 They can be switched on or off 
through interactions with other proteins or small mol-
ecules or by altering their positions within the cell in 
relation to their substrates.
Many  protein  kinases  have  a  highly  conserved 
catalytic domain.7,8 The domain consists of two lobes 
made of a polypeptide chain. A segment known as the 
“hinge region” joins the two lobes and allows them 
to rotate.8 The ATP molecule binds in a cavity created 
by the two lobes. The structure of this cavity is highly 
conserved  among  protein  kinases.6  Since  different 
kinases have very similar ATP binding sites,9,10 kinase 
inhibitors that target the site may not be sufficiently 
selective.11,12
The  Polo-like  kinase  (Plk)  family  members  are 
important  cell  cycle  regulators.3,4  The  four  known 
Polo-like  kinases,  Plk1,  Plk2,  Plk3,  and  Plk4,  all 
have a polo-box domain (PBD) at their C-terminus.13 
This PBD consists of either one (Plk4) or two polo-
box  motifs,  each  containing  about  80  residues.14 
  Regulation of Plks during the cell cycle is accom-
plished through their expression levels,15,16 positions 
within the cell influenced by PBD,13,17 and phospho-
rylation in the catalytic domain.18,19
A previous study20 showed that although the Polo 
box domains in each member of the Polo-like kinases 
family were similar, they were different and had spe-
cific binding affinities. According to this study, the 
PBD of Polo-like kinase 1 (Plk1), which consists of 
two polo boxes, is most similar to the one in Plk2, but 
not exactly alike. Plk3 is even less similar to Plk1. 
Plk4 has only one polo box and does not form a PBD 
binding pocket that is similar to the other Plk proteins. 
Therefore, potential Plk1 inhibitors could distinguish 
Plk1 from other Polo-like kinases.
Plk1, the best-characterized of the four Plk kinases, 
is a main regulator of mitosis.5,21 The roles of the other 
three kinases are less defined.5,21 Plk1 belongs to a 
group of highly conserved serine/threonine kinases. 
As a main mitotic regulator, Plk1 has an important 
role in cell proliferation.5,21,22
Plk1  has  been  implicated  in  certain  human 
cancers.21,23,24 It has been shown that Plk1 inhibition 
by RNA interference leads to mitotic arrest and apop-
tosis of cancer cells.25,26 Plk1 is, therefore, an attrac-
tive target for cancer drug research. Plk1, expressed 
only in dividing cells, does not seem to play signifi-
cant role in non-mitotic processes. Thus, a Plk1 inhib-
itor would act selectively on all rapidly dividing cells, 
while avoiding many side effects related to existing 
anti-mitotic drugs.27,28
Several  Plk1  inhibitors  have  been  identified  so 
far.21,29 These include scytonemin,30 purvalanol A,29 
and wortmannin.31 However, these have low selec-
tivity  and  express  similar  potencies  for  binding 
with  several  other  kinases  aside  from  Plk1.  Some 
Plk1 inhibitors, such as BI 2536,32,33 inhibit Plk134,35 
by  targeting  its  ATP  binding  site.  The  preserved 
structure of the site makes it difficult to selectively 
inhibit a specific kinase without the risk of nonspe-
cific binding.36,37 Instead of relying on targeting the 
ATP binding site, this study focuses on designing a 
molecule which binds to the PBD of Plk138,39 in order 
to design a specific inhibitor.
The PBD mediates proper cellular positioning of 
Plk1,13,17 which is necessary for mitosis.40 The Plk1 
PBD consists of two polo boxes, which are symmetri-
cal halves connected by a somewhat flexible hinge 
structure.41,38 Since PBD is unique to polo-like kinases, 
this domain may be a suitable target for development 
of selective Plk1 inhibitors.21
Poloxin, Thymoquinone, and Purpurogallin (PPG) 
were the only reported small molecules that potentially 
bind PBD of Plk1.42 Their structures were published 
elsewhere42 and shown here in Figure 1. Thymoqui-
none43 was found to inhibit the Plk1 PBD in vitro, 
albeit less selectively that Poloxin. Although previ-
ous studies44,45 found that Poloxin selectively bonded 
Plk1, Liao et al14 experimentally showed that PPG, 
but not Poloxin, bonded to the PBD. Both Poloxin 
and Thymoquinone stopped mitosis40 in cancer cells, 
apparently  by  impeding  the  correct  positioning  of 
Plk1.45 However, Poloxin did not show Plk1 PBD Targeted Inhibitors of Plk1
Bioinformatics and Biology Insights 2012:6  25
inhibition  in  another,  ELISA-based,  study.42  PPG 
caused cellular delocalization of Plk1, which stopped 
mitosis in a way that suggested it might interrupt the 
Plk1 function in vivo.46 Our goal was to computation-
ally design and study novel druglike small molecules 
that would selectively bind to the PBD of Plk1, thus 
potentially promoting apoptosis in cancer cells.
A promising small molecule inhibitor should have 
toxicity, metabolic stability, and transport properties 
similar to existing drugs. These properties are influ-
enced by the molecule’s hydrophilicity, size, mass, 
flexibility, and electronic bond distributions.47
The molecule’s hydrophilicity can be reliably eval-
uated47 using its logP value (logarithm of the octanol-
water partition coefficient). A low logP value indicates 
high hydrophilicity. It was shown previously47 that a 
molecule with logP , 5 is generally well absorbed by 
an organism.
The  absorption  is  also  significantly  determined 
by molecular solubility. High logS values (logarithm 
of  the  solubility  measured  in  mol/liter,  with  units 
removed) generally indicate good absorption. More 
than 80% of known drugs have logS . −4 (this value 
corresponds to a solubility of 0.1 mmol/liter).48 For 
most existing drugs −5 , logS , 1.47
A PSA value, which is the total surface area of all 
polar atoms in a molecule, can predict the molecule’s 
ability  to  permeate  cell  membranes,  such  as  those 
in intestinal walls and the blood-brain barrier.49 The 
PSA values of most commercial drugs are less than 
120 Å2.49
Molar masses of a vast majority of existing drugs 
are  less  than  500  g/moL.48  Molecules  with  greater 
molar  masses  are  harder  to  absorb.  The  number  of 
  rotatable bonds in a small molecule influences molec-
ular flexibility, which in turn impacts the molecule’s 
oral   bioavailability.50 Prior studies50 showed that good 
oral bioavailability is indicated by 10 or fewer rotatable 
bonds. Similarly, a molecule with fewer than 6   hydrogen 
bond donors may be a viable drug candidate.51
Plk1, a main regulator of mitosis, is often over 
expressed in cancers.21,52,53 In this work, we designed 
and  studied  drug  like  properties  of  putative  new 
small molecules that would selectively bind to, and 
thus  potentially  inhibit,  the  polo-box  domain  of 
Plk1.
Methodology
computational tools
The following software and servers were employed to 
design and evaluate molecules that could potentially 
inhibit Plk1 by interacting with its PBD: Protein Data 
Bank,54 Deep View,55 ArgusLab,56 Molinspiration,57 
and Osiris Property Explorer.48
Information on experimental structures and func-
tions of known molecules was obtained from Pro-
tein  Data  Bank  (PDB).  The  Deep  View  program 
was employed to visualize and compare molecular 
  structures.  Molecular  design  and  docking  studies 
were done using the Argus Lab program.
The numbers of  H-bond donors and rotatable bonds 
were  obtained  using  the  Molinspiration  program. 
Osiris Property Explorer was employed to calculate 
drug  like  properties  of  designed  molecules  and  to 
estimate  their  possible  mutagenic,  tumorigenic,  or 
reproductive risks. When a designed molecule con-
sists mostly of fragments frequently found in known 
drugs, the molecular Drug Likeness value calculated 
by the Osiris program is positive. The techniques and 
validation studies used to evaluate drug like proper-
ties by the Osiris and Molinspiration programs are 
given elsewhere.57,58
The Osiris program can alert if a molecule is likely 
to be toxic. Although the absence of an alert does 
not guarantee that a molecule is non-toxic, Osiris is 
a good prognostic tool. When tested on compounds 
known to cause mutations, Osiris properly indicated 
that 86% of them were toxic. Similarly, when tested 
on known drugs, the program predicted that only 12% 
of them were possibly toxic.58
No single drug like property guaranties that a mol-
ecule will be a viable drug candidate. Rather, a prom-
ising drug candidate should have optimized values 
of all drug like properties and no indicated toxicities. 
Osiris predicts overall molecular drug potential by 
using the values of logP, logS, molecular mass, Drug 
Likeness, and toxicity risks together to calculate the 
Drug Score of the molecule58
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Figure 1. Structures of (A) PPg, (B) Poloxin and (c) Thymoquinone.Jani and Dalafave
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Dataset
Experimentally-known three-dimensional   molecular 
structures  of  the  protein  kinases  were  obtained 
from Protein Data Bank (their PBD ID’s are given 
in parentheses): Plk1 (1UMW); ABL (3NSV), AKT 
(3O96), CDK2 (3LFS), CHK1 (1IA8), CLK1 (1Z57), 
GSK3b (1H8F), LCK (3MPM), LYN (3A4O), NEK2 
(2W5A), and PKA (3AGM). The structures of Pur-
purogallin  (PPG),  Poloxin,  and Thymoquinone  are 
shown in Figure 1.
Procedure employed
PPG, Poloxin, and Thymoquinone were docked in 
ArgusLab56 to each of the 11 kinases. The goal of the 
docking studies was to determine the relative binding 
specificities and to identify any binding patterns that 
would help design selective Plk1 inhibitors.
PPG was the most selective of the three molecules 
tested. It was found to bind only to Plk1 (at PBD) and 
LYN  kinases.  Thymoquinone  and  Poloxin  formed 
more stable bonds with other kinases than with Plk1 
and showed less selectivity than PPG. Different Plk1 
binding environments are utilized for PPG, Poloxin 
and Thymoquinone interactions.42 PPG binds to the 
PBD of Plk1, while Poloxin and Thymoquinone bind 
to the active, ATP-binding site of Plk-1. These are 
some of the reasons that PPG was chosen as a starting 
template to design new small molecules that would 
bind specifically to PBD of Plk1.
The binding environments of Plk1 PBD and LYN 
were carefully studied in the Deep View program55 
by examining properties of all amino acid residues 
within 10 Å of the PPG binding sites. The goal was to 
search for any chemical differences between the sites 
that could be exploited to design a molecule specific 
for Plk1 PBD that would not bind LYN or any other 
kinase.
The binding environments of LYN and the PBD 
of Plk1 were found to be remarkably similar to each 
other,  introducing  a  challenge.  Both  binding  sites 
contained 2 polar and neutral residues, 2 acidic resi-
dues, 1 or 2 basic residues, and 5 hydrophobic resi-
dues arranged similarly. The identities of these amino 
acids  were  also  very  similar.  Both  Plk1  and  LYN 
contained one each of serine, glycine, lysine, leucine, 
phenylalanine, and aspartic acid residues. This made 
it difficult to target specific residues in the PBD for 
binding specificity.
However, there were spatial differences between 
the two sites which could be exploited (Fig. 2). Atomic 
distances  between  corresponding  binding  residues 
within each binding site were measured in Deep View. 
It was found that relevant atomic distances within the 
PBD Plk1 binding site were greater than those within 
LYN by approximately 44%–67% (see Fig. 2).
Therefore,  a  larger  ligand  could  potentially  fit 
into this space in Plk1 and would be excluded from 
LYN’s smaller binding site. The flexible hinge struc-
ture of the PBD should also aid in allowing a larger 
ligand to fit into this space. LYN has no such flexible 
hinge structure and is therefore less likely to be able 
to change its conformation easily to accommodate a 
larger ligand.
Atoms with larger radii than those on the hydroxyl 
groups on PPG were added or substituted in the PPG 
molecule  to  create  a  larger  molecule. Atoms  were 
carefully chosen to achieve two goals: a sufficient 
increase in the size of the molecule without drasti-
cally decreasing its drug likeness by mass increase.
The  Osiris  and  Molinspiration  programs  were 
employed to test drug like properties of the designed 
molecules. The programs assessed each molecule’s 
mass,  logP  value,  solubility,  number  of  rotatable 
bonds, and hydrogen bond donors. Osiris also alerted 
for potential toxicities or mutagenicities and calcu-
lated a Drug Score for each molecule.
Three-dimensional structures of the designed mol-
ecules were optimized using the Molecule Builder 
and Semi empirical Geometry Optimization functions 
in the Argus Lab program. Docking of the molecules 
to the 11 kinases was done using the Argus Dock 
engine with flexible setting that permitted rotations 
of molecular bonds. Other docking parameters were: 
0.4 Å grid resolution; AScore scoring function; and 
ascore.prm parameter set. ArgusLab calculated bind-
ing energies of stable configurations a ligand could 
assume when docked to a given kinase.
Results and Discussion
Atomic substitutions and additions in the side groups 
of PPG were made using the Osiris program to design 
molecules with improved drug like properties, bet-
ter selectivity, and higher binding affinity to Plk1. 
  Substitutions of the −OH group bonded to the car-
bon in position 1 (Fig. 1) yielded favorable increase 
of drug scores. In particular, Cl and I substitutions Targeted Inhibitors of Plk1
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at this position resulted in the increase of drug score 
by over 150%. On the other hand, substitutions with   
Br and F lowered drug likeness scores. Substitutions 
of the same −OH group with Group 1A metals were 
also similarly favorable in terms of drug scores, but 
did not afford improved selectivity to Plk1.
Substitutions of the −OH group by Si, P, and S 
all yielded lower drug likeness values and lower drug 
scores. Most drug likeness values were between −1 
and −5. Drug scores were around 50%. Substitutions 
with C, H, and N gave drug scores of around 0.76 and 
drug likeness between 44%–64%.
Additions and substitutions of side-chains bonded 
to carbon atoms at positions 2–7 and 9–11 (Fig. 1) did 
not lead to improved drug like or selectivity proper-
ties of designed molecules. Addition of methyl and 
hydroxyl groups at position 8 yielded drug likeness 
scores of 40% and 17%, respectively. Additions of Si, 
S, and P at this position gave drug scores of less than 
50% and drug likeness values between −1 and −6. 
The most favorable improvement of both drug like 
properties  and  Plk1  selectivity  was  achieved  by 
simultaneous additions of side chains at position 8 
and substitutions of the −OH group at position 1, as 
shown in Figure 3.
Figure  3  shows  the  structures  of  ten  designed 
small molecules, identified as having suitable drug 
like properties and binding only to PBD of Plk1, and 
  possibly to LYN. Letters A–J designating each mol-
ecule in Figure 3 correspond to letters of designed 
molecules in Table 1. For comparison, the structure 
of PPG is shown in Figure 1.
The first five molecules in Figure 3 (A through E) are 
the most specific and drug like putative Plk1   inhibitors. 
Their  chemical  compositions  are:  IC11H7O4ONCl  (mol-
ecule A); IC11H6O4OCl (  molecule B);   ClOC11H6O4I 
(molecule  C);  NH2OC11H6O4I  (molecule  D);  and 
IOC11H6O4OCl (molecule E). Molecules F through J 
are less specific to Plk1. Their chemical composi-
tions are N(CH3)2C11H7O4 (  molecule F); NH2C11H6O4 
(molecule G); CH3C11H7O4 (molecule H); ClC11H7O4 
(molecule I); and IC11H7O4 (molecule J). Only mol-
ecule A was predicted to bind exclusively to Plk1 and 
to no other tested kinase.
As  can  be  seen  in  Figure  3,  all  ten  designed 
molecules  have  the  same  basic  double-ring  struc-
ture as PPG, with different side-chain substitutions. 
  Molecules A–E, which are more specific to the PBD 
of Plk1, have six side groups. Molecules F–J are less 
specific to the PBD of Plk1 and have five side groups. 
This is in agreement with the PBD Plk1 binding site 
being more spacious than the binding site of LYN.
The values of drug like properties of PPG and the 
ten designed molecules and their binding energies 
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Figure 2. PPg (gray) binding to (A) Plk1 PBD (pink) and (B) LYn (blue) with relevant atomic distances shown.
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with PBD of Plk1 are given in Table 1. The Osiris 
Property  Explorer  and  Molinspiration  programs 
were used to calculate the values of logP, logS, Drug 
Likeness,  Drug  Score,  and  toxicity  risks.  Similar 
values for the molar masses (MM), logP, and PSA 
were predicted by both programs. The number of 
rotatable bonds (nrotb), H-bond acceptors (nON), 
and H-bond donors (nOHNH) were calculated with 
Molinspiration. Toxicity risks and the values of Drug 
Likeness and Drug Score were predicted by Osiris. 
The ten designed molecules had no indicated tox-
icity risks and optimal values for their drug-related 
properties.
For  all  designed  molecules,  logP  #  3.50  and 
−3.85 # logS # −2.44. As discussed in the Introduc-
tion section, these values are well within the estab-
lished ranges for known drugs. The values for the 
polar surface area (PSA) of all ten molecules were 
between 77.8–113 Å2. This is also within the “drug 
like” range (,120 Å2). All ten molecules had molar 
masses between 218–397 g/moL. They also had 2 or 
fewer rotatable bonds, 5 or fewer H-bond donors, and 
between 4–6 H-bond acceptors. All 10 molecules had 
positive Drug Likeness values, ranging from 0.44 to 
1.9. The Drug Score values were between 66%–87%. 
As discussed earlier, these values should dependably 
predict47,49,50 the overall drug potential of the designed 
molecules.
As described in the Methodology section, the Argus 
Lab  program  was  then  used  to  dock  the  designed 
molecules to the studied kinases. Binding energies 
of the complexes formed by the designed molecules 
and PBD of Plk1 are given in Table 1. More negative 
binding energies indicate more stable complexes. As 
can be seen from Table 1, the binding energies ranged 
between −44.7 and −25.7 kJ/moL. These values are 
comparable to the binding energies of −38.3 kJ/moL 
and  −21.2  kJ/moL  obtained  for  the  PPG-Plk1  and 
PPG-LYN complexes, respectively.
The docking calculations showed that only mol-
ecule A (Fig. 3) was exclusively selective for PBD 
of Plk1. This molecule did not form stable configura-
tions with any of the other 10 tested kinases, including 
LYN. Since the binding site of LYN is smaller than 
the binding site of Plk1, molecule A was designed to 
be too big to fit into the LYN binding site, but small 
enough to fit into the Plk1 binding site.
The binding energy of the most stable configura-
tion of molecule A and PBD of Plk1 was −37.5 kJ/moL 
(Table 1). For molecule A, the logP value was 3.26, 
solubility −2.81, the PSA value 99.0 Å2, molecular 
mass 395 g/moL, and its drug likeness 0.75. The mol-
ecule also had 2 rotatable bonds (nrotb), 6 H-bond 
acceptors (nON), and 4 H-bond donors (nOHNH). 
These factors combined to give a drug score of 70%. 
Figure 4, created in the Deep View program, shows 
molecule A bound to the PBD of Plk1.
Molecule B (Fig. 3) was similar in structure but 
slightly smaller in size than molecule A. However, 
it had only one stable pose when docked to LYN, 
compared  to  a  dozen  stable  poses  when  docked 
to  Plk1.  Its  binding  energies  with  LYN  and  the 
most stable pose with Plk1 PBD were calculated to 
be −18.5 kJ/moL and −26.5 kJ/moL, respectively.
Table 1. Drug-related properties of the designed molecules.
Molecule logp logs psA  
(Å2)
MM  
(g/moL)
nrotb nOn nOHnH Drug 
likeness
Drug  
score
energya  
(kJ/moL)
A 3.26 −2.81 99.0 395 2 6 4 0.75 70% −37.5
B 3.50 −3.48 87.0 380 1 5 3 0.75 68% −26.5
c 3.50 −3.12 87.0 380 1 5 3 0.81 71% −26.5
D 2.30 −3.85 113 360 1 6 5 0.97 69% −27.0
e 3.46 −3.16 96.2 397 2 6 3 0.36 66% −25.7
F 1.93 −2.44 81.0 247 1 5 3 1.9 87% −37.2
g 1.31 −2.48 104 219 0 5 5 0.64 78% −38.2
h 2.28 −2.75 77.8 218 0 4 3 0.44 74% −43.8
I 2.50 −3.14 77.8 239 0 4 3 0.56 73% −44.0
J 2.91 −3.42 77.8 330 0 4 3 1.1 72% −44.7
PPg 1.31 −2.11 97.98 220 0 5 4 0.47 46% −38.3
note: aBinding energy of the most stable complex of Plk1 PBD with the designed molecules and PPg.Targeted Inhibitors of Plk1
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The  other  eight  designed  molecules,  C–J  in 
  Figure 3, were less selective. However, they all bonded 
more favorably to Plk1 than to LYN. None of them 
bonded to any of the other nine studied kinases.
Molecules C, D, and E in Figure 3 bonded LYN 
with a relatively small number of stable configura-
tions, making it less likely that these reactions would 
occur in an actual cellular environment. LYN made 
only 2 stable poses with each of the molecules C and 
D and 6 stable poses with molecule E.
Molecules F–J in Figure 3 formed numerous stable 
conformations with both Plk1 and LYN and were less 
specific than the first five molecules. However, each 
of these molecules had good drug scores and bonded 
more favorably to Plk1 than to LYN, but not to any of 
the other nine kinases.
All ten designed molecules bonded Plk1 at its PBD 
binding site, the same as PPG.14 These findings sug-
gest that the molecules might be able to interrupt the 
Plk1 cellular function in a similar manner as PPG.
PBD  of  Plk1  is  as  a  phosphoresidue-binding 
domain. PBD binds to a phosphopeptide by employ-
ing hydrogen bonds.59 The designed molecules pre-
sented in this paper are predicted to interact with 
the  PBD  not  with  hydrogen  bonds,  but  via  pi-pi 
stacking due to the aromatic ring structures found 
in  each  designed  molecule.  In  these  hydrophobic 
interactions,  water  is  displaced  from  the  binding 
pocket and is replaced by the ligand.60 This is more 
energetically beneficial than the hydrogen bonding 
which would occur between the PBD and a phos-
phopeptide. As a result, the designed molecules are 
predicted  to  “oust”  any  phosphopeptide  and  thus 
interfere with the Plk1function. By preventing phos-
phopeptide binding of the PBD, centrosomal local-
ization is prevented.38
The designed molecule A (Fig. 3) selectively binds 
the PBD of Plk1, has acceptable values of druglike 
properties,  and  no  indicated  toxicities.  It  is  also 
  structurally similar to PPG, which is known to bind 
PBD  of  Plk1. Therefore,  molecule A  may  warrant 
further experimental studies to determine its potential 
usefulness as a drug.
conclusions
In this research, several novel drug like small mol-
ecules were computationally designed. Studies indi-
cate that the molecules could potentially make stable 
complexes with PBD of Plk1. One of the molecules, 
IC11H7O4ONCl, bonded selectively to Plk1 and to 
no other studied kinases.
All  ten  molecules  were  found  to  have  drug 
like properties, such as logP # 5, −5 # logS # 1, 
PSA  ,  120  Å2,  molar  masses  below  500  g/moL, 
fewer than 10 rotatable bonds and hydrogen bond 
acceptors, and fewer than 6 hydrogen bond donors. 
All  of  the  molecules  had  positive  values  of  Drug 
Likeness  and  overall  Drug  Scores  between  66%–
87%. They all produced stable complexes with PBD 
of Plk1, and possibly with LYN. The binding ener-
gies of the complexes with Plk1 were between −44.7 
and −25.7 kJ/moL. These results, coupled with prior 
experimental studies of PPG, strongly suggest that 
the molecules designed here might be good candi-
dates for designing drug like Plk1 inhibitors.
One of the designed molecules (IC11H7O4ONCl) 
bonded specifically to PBD of Plk1. Drugs based on 
this molecule could be useful against tumors with 
over  expressed  Plk1.  Such  drugs  could  selectively 
bind this kinase and thus lead to fewer side effects 
than a less selective drug.
Molecules designed here formed stable bonds with 
PBD of Plk1 in silico. While laboratory syntheses of 
the molecules have not been done, it should be noted 
that an experimentally known molecule, PPG, was 
used as a model to design all ten molecules. The mer-
its of the designed molecules for anticancer applica-
tions eventually needs to be evaluated in vitro and, if 
warranted, in vivo.
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